Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

Let’s talk about insider trading. Not the illegal kind, but the perfectly normal – and fully legal – trading by top-level ...

Nuvalent's promising lead candidates and strong investor interest has put the stock under the spotlight. Read more about the ...

本次ESMO大会进一步更新报道了中国桥接研究的数据。这项Ⅱ期研究招募了对伊马替尼治疗失败或不耐受的GIST成年患者，随机（1:1）接受瑞派替尼150 mg每日一次（QD）或舒尼替尼50 mg ...

历经多年不懈探索，奥希替尼在 EGFR 突变 NSCLC 治疗领域不断突破，至今已 8 次荣登 NEJM，成为其传奇历程的见证。与此同时，奥希替尼的应用范围不断扩大，从晚期扩展到早期，从后线治疗走向前线治疗，从单药治疗到联合治疗，其在国内已有 4 个适应症获批上市，是目前国内适应症范围最广*的 EGFR-TKI。而且，奥希替尼是目前唯一*的一线、二线及辅助治疗适应症均纳入医保的三代 ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

Chronic Myeloid Leukemia (CML) affects millions worldwide, including a rising number in India. Effective management involves ...